By Steven Bulwa:
The Internet has democratized the availability of information and Seeking Alpha is a microcosm of the best aspects of this change. Independent analysts without the prejudice of the financial entanglements of Wall Street bankers are now just as able to offer opinions and disseminate information as that long-standing establishment. For investors, this is a welcome change and an opportunity to identify more opportunities and make better-informed valuable independent investment decisions. Dendreon (DNDN) has long been a polarizing proposition for investors, a company with a potentially blockbuster drug that has as many adamant supporters as inexorable dissenters. A series of recent articles on Seeking Alpha have pushed me firmly into the bull camp.
Dendreon Polarizes Investors
Dendreon is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics for treating cancer. The company’s product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a wide